parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in pancreatic acinar cells	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 26	0.91
pathways Reactome	3 pathways; mostly growth signalling	0.60

No case: the score is under the bar. Receipt 11635

receipt 11644: SHC2 in dopamine neurons, braak

power: full sample -0.36 (p 0.145, n 18), 95% CI -0.71 to +0.13. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.33 (p 0.188, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.40 (p 0.103, n 18). could be the mix.
skeptic: leave-one-out range -0.50 to -0.27, sign flips 0; without severely affected donors -0.36 (p 0.145, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SHC2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 11643: SHC2 in oligodendrocytes, braak

power: full sample -0.08 (p 0.741, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.09 (p 0.722, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.09 (p 0.715, n 18). could be the mix.
skeptic: leave-one-out range -0.21 to +0.03, sign flips 4; without severely affected donors -0.08 (p 0.741, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SHC2 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts